Cure rate remains 90%, case detection has not started
According to the National Cancer Institute in Brazil – INCA, prostate cancer is the second most common (10.2%) in men, after skin cancer and melanoma. Considered a “third life cancer”, it mainly affects people over the age of 60. Diagnostic methods have contributed to an increase in life expectancy, a high percentage of the probability of cure, reaching 90% in cases of early detection.
Blue emerged in November 2003 in Melbourne, Australia from the initiative of two friends who were hanging out in a pub and were introduced to moustaches, which were out of fashion at the time. So, inspired by a colleague’s mother’s campaign that was raising money to tackle breast cancer, the friends came up with the idea of linking Bigod with awareness of men’s health. It is recommended to grow your mustache after November as the 17th will be celebrated as World Day to Fight Prostate Cancer. That year, about 30 friends were able to participate in the campaign and, since many people were interested in mustache hair, the story unfolded. Not the next year, it came out November Foundation – The name I saw in the words Mustache (“mustache”) and november (“November”) –, a non-profit organization that aims to raise funds to combat prostate cancer. An online platform was also created to receive gifts, where people could share photos of their mustache growth or for more. As two years passed, the campaign attracted more and more participants and spread to more than 20 countries, also becoming known as “”.no Shave November”, “Novembro Same Beard “. The movement began in Brazil in 2008, led by the Instituto Lado a Lado for Life in collaboration with the Brazilian Society of Urology.
Since diagnosis involves the final touch, an examination that is still surrounded by controversies, many people perceive the task as preconceived. In this sense, one of the two objectives of Blue November is to break these taboos and make the male population aware that health care should be placed above these barriers.
The prostate is a gland that occurs only in individuals born male, and which is located in the lower abdomen. It is responsible for producing the nutrients and fluids that make up sperm. The logo is located at the bottom corner and in front of the challenge. Passing through its interior, it passes to the urethra, an anatomical detail that explains the cause of prostatic changes that cause difficulty urinating, which is common in men over 50 years of age. In most cases, this difficulty is caused by prostatic enlargement, which occurs as the disease progresses and is called benign prostatic hyperplasia.
Prostate cancer settles in any area of the gland. As it grows, it gradually takes over the right and left sides of the prostate. In the most advanced stages, it persistently invades the capsule that lines the organ, then spreads to the tissues surrounding it, including the seminal vesicles. In more large tumors, the patient experiences difficulty urinating, a burning sensation and a weak urinary tract sensation, remembering to urinate several times at night, a drop of urine after completing urination and, sometimes , there is blood loss and the appearance of blood. Sperm. As time passes, malignant cells can infect adjacent lymph nodes, enter the bloodstream, and attack other organs.
There are basically two initial tests to check for signs and symptoms of possible prostate cancer and to find out whether the disease is developing: the clinical touch test and the PSA test (a blood test that measures a type of protein. Prostate – Prostate specific antigen – PSA. High levels of this protein can mean cancer, but can also mean benign symptoms of prostate).
Some factors can increase a person’s chance of developing prostate cancer:
- Idade: The risk increases as two years pass. In Brazil, nine times as many men over the age of 55 are diagnosed with prostate cancer.
- History of cancer in the family: Individuals whose father or mother had prostate cancer before the age of 60 are part of the risk group.
- Overweight and obesity: Recent studies have shown that overweight individuals have a higher risk of developing prostate cancer.
How to save? It is already proven that a diet rich in fruits, vegetables, legumes, cereals and whole grains and low in fat, mainly of animal origin, helps to reduce the risk of developing cancer, as well as other non- Also reduces infectious chronic diseases. In this sense, other healthy habits are also recommended, such as doing at least 30 minutes of physical activity a day, maintaining an appropriate weight for your height, reducing alcohol consumption and not smoking.
When it comes to treatment, there are many factors that influence it, but quick access to healthcare is the most important. As medicine advances, as an early and specific diagnosis is made for each tumor, there will be multiple treatments. Not only in Brazil, there are some technology-based companies that have been able to develop revolutionary tests. This is the case of InvitroQ Brazil, which is developing the Onco-PDO test (Patient Derived Organoids) by investing in organoid technology. In this case, the patient’s cells are cultured and tested against different chemotherapy drugs, analyzing how they react to different treatments.
It is a three-dimensional cell culture, which best reflects in vitro conditions observed in vivo tumor of your origin, The Onco-PDO test shows that each patient is unique, and this helps the doctor design the best therapeutic strategy for that specific patient. Some tumors are found to be resistant to certain drugs and knowing in advance the responses of a patient’s tumor cells to various treatments in the laboratory helps oncological doctors make decisions. The advantage is that, rather than making predictions about how the cancer might respond to a therapy, the Onco-PDO test allows you to specifically verify the effect of this therapy on the patient’s tumor and the living cells that form the cancer. Allows to work directly. each case.
The Onco-PDO test, available in Brazil for breast, lung, colorectal, pancreatic, gastric, prostate and ovarian cancer, allows the doctor to select 8 out of 60 drugs for testing and the results will show how the cells react in the laboratory. Do it. The report generated in 21 days provides information on how the organoids obtained from the patient respond to the various treatments tested. The Onco-PDO test is available for pigtails throughout Brazil. For more information, consult InvitroQ Brazil.
The future of medicine depends on accuracy. So that new devices can be used, talk to your doctor for an accurate assessment and analysis of treatment options!
About InvitroQ Brazil
InvitroQ Brazil began operations in the country in 2020, developing and commercializing various bioanalytical technologies, including 3D cell culture.